Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 22:58, 29 January 2012 (Updating {{drugbox}} (no changed fields - updated 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'CAS_number_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacolog...). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Adecatumumab (MT201) is a recombinant human monoclonal antibody which is used to target tumor cells. It binds to the epithelial cell adhesion molecule (EpCAM - CD326).

Adecatumumab has been used in clinical studies of treatment in prostate and breast cancers.

References

1. Oberneder R, Weckermann D, Ebner B; et al. (2006). "A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients". Eur. J. Cancer. 42 (15): 2530–8. doi:10.1016/j.ejca.2006.05.029. PMID 16930989. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
2. Prang N, Preithner S, Brischwein K; et al. (2005). "Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines". Br. J. Cancer. 92 (2): 342–9. doi:10.1038/sj.bjc.6602310. PMC 2361858. PMID 15655555. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibodies for tumors
• Monoclonal antibody stubs
• Antineoplastic and immunomodulating drug stubs